SELLAS Life Sciences: These Phase-3 Data Could Change Everything

SELLAS Life Sciences Group is a US-based biotechnology company in the late stage of clinical development, specializing in novel cancer therapies. At the forefront are immunotherapies and targeted agents against aggressive blood cancers such as acute myeloid leukemia (AML). Particularly important for investors is the ongoing Phase-3 study around the drug Galinpepimut-S (GPS), which targets the WT1 protein found in various tumor types. At the same time, SELLAS is developing SLS009, a selective inhibitor intended for high-risk AML. The stock is considered...